iHeart Japan Corporation

9:00 AM - 9:15 AM (JST), Wednesday, March 6, 2019 ・ 2nd Floor

Developing an allogeneic regenerative medicinal product for severe heart failure, which is made from iPS cell.

Company Type:

Privately Funded Company

Company Website:

Company HQ State:

Not Provided

Company HQ Country:

Japan

Year Founded:

2013

Main Therapeutic Focus:

Regenerative Medicine

Lead Product in Development:

IHJ-301: allogeneic regenerative medicine for heart failure

Development Phase of Primary Product:

Pre-Clinical

Number Of Unlicensed Products (For Which You Are Seeking Partners):

2